secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0000950170-22-022600
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC reports Q3 2022 cash of $218M; pipeline studies on track for data in 1H 2023
--------------------------------------------------------------------------------

- Cash and investments of $218.0M as of Sep 30, 2022; expected to fund operations into 2H 2024.
- R&D expenses $14.7M (up from $12.9M); G&A $6.0M (up from $5.6M); IPR&D $5.0M milestone for ORIC-114.
- Initial Phase 1b data for ORIC-533, ORIC-114, and ORIC-944 expected in 1H 2023.
- FDA cleared US IND for ORIC-114; Phase 1b enrolling in South Korea with expansion to US.
- Preclinical data on ORIC-533 (CD73 inhibitor) to be presented at ASH Annual Meeting Dec 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017022022600/0000950170-22-022600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017022022600/oric-20221107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer